Serum tumor biomarkers as a surrogate for radiographic assessment of non-small cell lung cancer.

• DOI: 10.1200/jco.2023.41.16_suppl.e21076
• Publication Date: 2023-06-04T16:18:19Z
• Authors: Scott Strum; Mark David Vincent; Meghan Gipson; Eric McArthur; Daniel Adam Breadner
• Keywords: Surrogate endpoint; Regimen

e21076 Background: Conventional tumor markers are positioned to serve as a useful adjunct in lung cancer management. However, most studies this field have been specific particular disease stage or treatment regimen. Thus, the purpose of research was assess whether three minimally invasive, low-cost serum (CEA, CA19-9, and CA-125) held associations with radiographic clinical outcomes non-small cell (NSCLC) patients who received systemic therapy more comprehensive patient population. Methods: This single-center retrospective study NSCLC treated between January 2016 August 2020. Serum were statistically analyzed for differences responded progressed (RECIST 1.1 iRECIST criteria), demographic characteristics, all-cause mortality pre-defined populations. Disease response assessed radiographically using RECIST criteria. Results: From 533 screened, 165 met inclusion Of these, 50.9% male 49.1% female. 69.7% had IV at baseline. The proportion an elevated CEA, CA-125, CA19-9 baseline 58.8%, 50.9%, 30.3%, respectively. A subset 92 paired scans, from which median (IQR) fold-change nadir progression 2.13 (IQR 1.24 - 3.02; p < 0.001) CEA (n = 47), 1.46 1.13 2.18; 46), 1.53 0.96 2.12; CA-125 47). Median 0.50 0.27, 0.95; 39), 1.08 0.74, 1.61; 0.99) 35), 0.47 0.18, 1.26; 0.008) 35). Lastly, not associated difference overall survival (HR 1.05, 95% CI 0.63-1.74, 0.84) within total Conclusions: levels significantly different than progressed. those responded. These cost-effective may important decision making. Analysis controlled trial is warranted.